PAVmed (NASDAQ:PAVM) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
PAVmed beat estimated earnings by 30.0%, reporting an EPS of $-0.14 versus an estimate of $-0.2.
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 75 percent decrease over losses of $(0.08) per share from the same period
Companies Reporting Before The Bell
• 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million.
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (NASDAQ:LUCD) (“Lucid”), a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ))
Gainers
Kidpik Corp. (NASDAQ: PIK) shares surged 158.2% to settle at $4.75 on Thursday after the company announced a partnership with The Walt Disney Co.
PAVmed Inc. (NASDAQ:PAVM, PAVMZ)))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company, today announced that physicians at the Clinica Porto Azul in Barranquilla,